Research Background: Same Medication, Different Outcomes The GLP-1 receptor agonists, hailed as game-changers in obesity treatment, have shown excellent weight loss effects but with significant variability in patient responses, ranging from minimal weight loss to severe nausea. To elucidate the underlying causes of this individual variability, the research team conducted a meticulous analysis of large-scale genomic data and clinical records.

Key Findings: 12 Genetic Landmarks Determining Treatment Response The study identified 12 core genetic variants that directly influence the response to GLP-1 treatment.

Mechanism of Action: The Link Between Genes and Lipid Metabolism The discovered genetic variants were not merely statistical correlations but were closely associated with actual gene expression networks and adipocyte metabolic pathways. This suggests that genetic differences can fundamentally alter the body's metabolic response to medication.

Outlook: Precision Obesity Treatment Without Trial and Error This study laid the foundation for a 'precision diagnostic model' that enables the selection of the most effective and safe medication for each patient based on their genetic information. The research team plans to validate the efficacy of these markers through future clinical trials and develop a precision medicine strategy for practical application in clinical settings.